Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. ARM
5. QCOM
6. EXPE
7. CPAY
8. EW
9. RPD
10. MNTN

Go back to Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'

United Therapeutics Corp. (UTHR) PT Raised to $733 at Jefferies

March 30, 2026 10:26 AM EDT

Jefferies analyst Roger Song raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $733.00 (from $668.00) while maintaining a Buy rating.

The analyst comments "Bottom line. Topline of 2nd Tyvaso Ph3 study for IPF, TETON-1 (US/ Canada) exceeded investors/ our expectations, even better than... More

United Therapeutics Corp. (UTHR) PT Raised to $660 at TD Cowen, 'remains a top pick'

March 30, 2026 8:33 AM EDT

TD Cowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $660.00 (from $575.00) while maintaining a Buy rating.

The analyst comments "UTHR announced that the second Ph. III study of Tyvaso for IPF (TETON-1) hit the primary... More